A Phase 3 interventional study of ALD403 and Placebo in Migraine Disorders, sponsored by Alder Biopharmaceuticals, Inc.. Completed at 87 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-05-14.
Sponsored by Alder Biopharmaceuticals, Inc. (part of H. Lundbeck A/S) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.
Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 3rd largest by enrollment, is the only one that started in 2015, is one of 13 in phase 3, and was the 4th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–65
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 12–17
Dr George Medvedev · Sites in Canada
Ages 19–75
By country, each count listing its studies:
eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 898 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 193 across the 21 interventional studies. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 21 have an industry lead sponsor. The 5 most frequent:
This study is registered under Alder Biopharmaceuticals, Inc., one of the names counted as H. Lundbeck A/S. Under that name alone:
Alder Biopharmaceuticals, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
23 studies in Migraine Disorders by H. Lundbeck A/S: 3 open now, 3 under way, 3 of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 23 studies in Migraine Disorders by H. Lundbeck A/S, this one is the 3rd largest by enrollment, is the only one that started in 2015, is one of 11 in phase 3, and was the 4th registered.
H. Lundbeck A/S’s Migraine Disorders studies by the year they started, since 2012.
3 of the studies testing eptinezumab in Migraine Disorders that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04965675Phase 3H. Lundbeck A/SA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | 2027-03-26 |
| NCT07191145Phase 3Sunnybrook Health Sciences CentreEary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) | 2027-06-30 |
| NCT05897320Phase 3H. Lundbeck A/SA Study of Eptinezumab in Pediatric Participants With Episodic Migraine | 2027-07-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies testing eptinezumab in Migraine Disorders, from their registry updates:
Among H. Lundbeck A/S’s 23 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess ALD403 in the prevention of migraine headache in frequent episodic migraineurs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
History of migraine ≥ 12 months with
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALD403 Dose Level 1 (IV)
Drug: ALD403
ALD403 Dose Level 2 (IV)
Drug: ALD403
ALD403 Dose Level 3 (IV)
Drug: ALD403
Placebo (IV)
Drug: Placebo
Also known as: Eptinezumab-jjmr, Vyepti
Change From Baseline in Monthly Migraine Days (Weeks 1-12)
Monthly migraine days are summarized in 28-day intervals, and averaged across Weeks 1-12
Time frame: Week 1-12
75% Migraine Responder Rate
Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 12, as compared with baseline.
Time frame: Week 1-12
75% Migraine Responder Rate
Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 4, as compared with baseline.
Time frame: Week 1-4
50% Migraine Responder Rate
Participants with an average reduction in migraine days of at least 50% over Weeks 1 to 12, as compared with baseline
Time frame: Week 1-12
Percentage of Participants With a Migraine on the Day After Dosing
The percentage of participants with a migraine on the day after dosing, where Day 0 is treatment day and Day 1 is the day after dosing
Time frame: 1 day
75% Headache Responder Rate
Participants with an average reduction in headache days of at least 75% over Weeks 1 to 12, as compared with baseline.
Time frame: Week 1-12
50% Headache Responder Rate
Participants with an average reduction in headache days of at least 50% over Weeks 1 to 12, as compared with baseline.
Time frame: Week 1-12
100% Migraine Responder Rate
Participants with a reduction in migraine days of 100% over Weeks 1 to 12, as compared with baseline
Time frame: Week 1-12
100% Headache Responder Rate
Participants with a reduction in headache days of 100% over Weeks 1 to 12, as compared with baseline.
Time frame: Week 1-12
Change From Baseline in Acute Migraine Medication Days (Weeks 1-12)
The change in number of days with any triptan or ergotamine use as recorded in the eDiary.
Time frame: Week 1-12
Change From Baseline in Average Daily Migraine Prevalence to Week 4
The change in the percentage of days where a participant has a migraine from baseline to Week 4.
Time frame: Baseline to Week 4
Change From Baseline to Week 12 in Percentage of Migraines With Use of Acute Medication
The percentage of migraines with acute medication usage. Participants with no migraines will be included with a rate of zero.
Time frame: Week 1-12
Change From Baseline to Week 12 in Percentage of Headaches With Use of Acute Medication
The percentage of headaches with acute medication usage. Participants with no headaches will be included with a rate of zero.
Time frame: Week 1-12
Change From Baseline in Monthly Headache Days (Weeks 1-12)
Monthly headache days are summarized in 28-day intervals, and averaged across Weeks 1-12.
Time frame: Week 1-12
Percent of Headaches With Severe Intensity
Summary of percent of headaches with severe intensity over Weeks 1-12.
Time frame: Week 1-12
Percent of Migraines With Severe Intensity
Summary of percent of migraines with severe intensity over Week 1-12.
Time frame: Week 1-12
Change From Baseline in Monthly Migraine Hours (Weeks 1-12)
Migraine hours are the sum of the duration of migraines within 4 week intervals, and the average 4 week duration within 12 week intervals.
Time frame: Week 1-12
Change From Baseline in Monthly Headache Hours, Weeks 1-12
Headache hours are the sum of the duration of headaches within 4 week intervals, and the average 4 week duration within 12 week intervals.
Time frame: Week 1-12
Change From Baseline of Short Form Health Survey (SF-36 v 2.0) Scale Scores
The SF-36 is a health survey containing 36 questions consisting of eight scaled scores to measure quality of life over the past 4 weeks. All scales are on a range of 0 to 100, with 0 being the worst and 100 being the best. Scales are reported separately. Increases from baseline indicate improvement.
Time frame: Baseline to Week 12
Health Related Quality of Life (EQ-5D-5L) at Week 12
The EQ-5D-5L is a descriptive system of health-related quality of life states consisting of 5 dimension/questions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension.
Time frame: Week 12
Change in Baseline of Allodynia Symptom Checklist-12 (ASC-12) Total Score
The ASC-12 includes 12 questions about the frequency of various allodynia symptoms in association with headache attacks. For individuals with more than one type of headache, questions are directed to the "most severe type of headache." Each item is measured in a Likert type scale option with response categories: "Does not apply to me", "never", "rarely", "less than half the time", and "half the time or more". ASC items were scored as 0 (i.e., never, rarely or does not apply to me), 1 (less than half the time), and 2 (half the time or more), yielding scores that ranged from 0 to 24. If a single item is missing, it is scored as a 0. If more than one item is missing the total score will be missing. The interpretation of the total score is, 0-2: none; 3-5: mild; 6-8: moderate; greater than or equal to 9: severe.
Time frame: Baseline to Week 12
| Milestone | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| Started | 224 | 225 | 224 | 225 |
| Participants treated | 222 | 221 | 223 | 222 |
| Completed | 169 | 172 | 170 | 165 |
| Not completed | 55 | 53 | 54 | 60 |
| Withdrew: Adverse event | 3 | 3 | 2 | 1 |
| Withdrew: Lack of efficacy | 2 | 3 | 2 | 8 |
| Withdrew: Lost to follow-up | 22 | 16 | 12 | 17 |
| Withdrew: Physician decision | 1 | 1 | 3 | 0 |
| Withdrew: Withdrawal by subject | 16 | 9 | 20 | 9 |
| Withdrew: Study burden | 10 | 16 | 12 | 22 |
| Withdrew: Other | 1 | 5 | 3 | 3 |
Monthly migraine days are summarized in 28-day intervals, and averaged across Weeks 1-12
| Migraine Days | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| Change From Baseline in Monthly Migraine Days (Weeks 1-12) | -4.3 ± 3.42 | -3.9 ± 3.23 | -4.1 ± 3.22 | -3.1 ± 3.70 |
Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 12, as compared with baseline.
| Participants | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| 75% Migraine Responder Rate | 66 | 49 | 55 | 36 |
Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 4, as compared with baseline.
| Participants | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| 75% Migraine Responder Rate | 70 | 68 | 67 | 45 |
Participants with an average reduction in migraine days of at least 50% over Weeks 1 to 12, as compared with baseline
| Participants | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| 50% Migraine Responder Rate | 125 | 110 | 112 | 83 |
The percentage of participants with a migraine on the day after dosing, where Day 0 is treatment day and Day 1 is the day after dosing
| Percentage of participants | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| Percentage of Participants With a Migraine on the Day After Dosing | 13.9 | 14.8 | 17.3 | 22.5 |
Participants with an average reduction in headache days of at least 75% over Weeks 1 to 12, as compared with baseline.
| Participants | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| 75% Headache Responder Rate | 42 | 28 | 34 | 23 |
Participants with an average reduction in headache days of at least 50% over Weeks 1 to 12, as compared with baseline.
| Participants | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| 50% Headache Responder Rate | 113 | 98 | 98 | 74 |
Participants with a reduction in migraine days of 100% over Weeks 1 to 12, as compared with baseline
| Participants | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| 100% Migraine Responder Rate | 9 | 1 | 4 | 4 |
Participants with a reduction in headache days of 100% over Weeks 1 to 12, as compared with baseline.
| Participants | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| 100% Headache Responder Rate | 6 | 0 | 4 | 2 |
The change in number of days with any triptan or ergotamine use as recorded in the eDiary.
| days | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| Change From Baseline in Acute Migraine Medication Days (Weeks 1-12) | -0.8 ± 1.77 | -0.9 ± 2.00 | -0.6 ± 1.62 | -0.4 ± 1.27 |
The change in the percentage of days where a participant has a migraine from baseline to Week 4.
| percentage of days with migraine | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| Change From Baseline in Average Daily Migraine Prevalence to Week 4 | -14.9 ± 19.78 | -13.8 ± 19.27 | -15.1 ± 17.83 | -9.7 ± 19.33 |
The percentage of migraines with acute medication usage. Participants with no migraines will be included with a rate of zero.
| percentage of acute medication migraines | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| Change From Baseline to Week 12 in Percentage of Migraines With Use of Acute Medication | 62.08 ± 38.46 | 66.58 ± 34.13 | 69.11 ± 33.72 | 71.44 ± 34.59 |
The percentage of headaches with acute medication usage. Participants with no headaches will be included with a rate of zero.
| percentage of acute medication headaches | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| Change From Baseline to Week 12 in Percentage of Headaches With Use of Acute Medication | 63.09 ± 36.87 | 66.85 ± 33.65 | 67.84 ± 33.59 | 70.95 ± 33.43 |
Monthly headache days are summarized in 28-day intervals, and averaged across Weeks 1-12.
| headache days | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| Change From Baseline in Monthly Headache Days (Weeks 1-12) | -4.5 ± 3.96 | -4.0 ± 3.30 | -4.4 ± 3.24 | -3.3 ± 3.51 |
Summary of percent of headaches with severe intensity over Weeks 1-12.
| percentage of severe intensity headaches | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| Percent of Headaches With Severe Intensity | 17.06 ± 22.03 | 19.84 ± 24.83 | 21.20 ± 26.60 | 21.68 ± 22.67 |
Summary of percent of migraines with severe intensity over Week 1-12.
| percentage of severe intensity migraines | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| Percent of Migraines With Severe Intensity | 19.07 ± 23.46 | 22.23 ± 26.30 | 24.43 ± 28.15 | 26.01 ± 24.99 |
Migraine hours are the sum of the duration of migraines within 4 week intervals, and the average 4 week duration within 12 week intervals.
| migraine hours | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| Change From Baseline in Monthly Migraine Hours (Weeks 1-12) | -42.9 ± 49.91 | -35.3 ± 47.85 | -37.8 ± 50.17 | -23.8 ± 50.91 |
Headache hours are the sum of the duration of headaches within 4 week intervals, and the average 4 week duration within 12 week intervals.
| headache hours | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| Change From Baseline in Monthly Headache Hours, Weeks 1-12 | -42.0 ± 56.67 | -34.2 ± 49.19 | -38.8 ± 50.45 | -24.5 ± 48.15 |
The SF-36 is a health survey containing 36 questions consisting of eight scaled scores to measure quality of life over the past 4 weeks. All scales are on a range of 0 to 100, with 0 being the worst and 100 being the best. Scales are reported separately. Increases from baseline indicate improvement.
| score on a scale | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| Physical Functioning | 0.9 ± 5.78 | 1.2 ± 6.88 | 0.9 ± 6.74 | 0.3 ± 6.43 |
| Role Physical | 3.0 ± 6.54 | 2.3 ± 7.65 | 2.4 ± 7.72 | 2.2 ± 6.78 |
| Bodily Pain | 4.5 ± 8.27 | 4.3 ± 8.37 | 3.5 ± 9.12 | 2.3 ± 8.70 |
| General Health | 1.2 ± 6.78 | 0.7 ± 7.22 | 0.6 ± 7.54 | 0.0 ± 6.52 |
| Vitality | 2.3 ± 7.91 | 1.8 ± 8.36 | 0.2 ± 8.61 | 1.7 ± 7.43 |
The EQ-5D-5L is a descriptive system of health-related quality of life states consisting of 5 dimension/questions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension.
| Participants | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| Mobility — No problems | 183 | 181 | 181 | 179 |
| Mobility — Slight problems | 21 | 18 | 16 | 15 |
| Mobility — Moderate problems | 4 | 6 | 3 | 4 |
| Mobility — Severe problems | 0 | 1 | 1 | 0 |
| Mobility — Extreme problems | 0 | 0 | 0 | 0 |
| Self-care — No problems | 206 | 201 | 198 | 195 |
| Self-care — Slight problems | 2 | 4 | 3 | 3 |
| Self-care — Moderate problems | 0 | 1 | 0 | 0 |
| Self-care — Severe problems | 0 | 0 | 0 | 0 |
| Self-care — Extreme problems | 0 | 0 | 0 | 0 |
| Usual Activities — No problems | 177 | 173 | 176 | 172 |
| Usual Activities — Slight problems | 29 | 22 | 21 | 19 |
| Usual Activities — Moderate problems | 2 | 10 | 3 | 7 |
| Usual Activities — Severe problems | 0 | 0 | 1 | 0 |
| Usual Activities — Extreme problems | 0 | 1 | 0 | 0 |
| Pain/Discomfort — No problems | 113 | 116 | 123 | 110 |
| Pain/Discomfort — Slight problems | 75 | 65 | 57 | 68 |
| Pain/Discomfort — Moderate problems | 19 | 24 | 18 | 18 |
| Pain/Discomfort — Severe problems | 1 | 1 | 3 | 2 |
| Pain/Discomfort — Extreme problems | 0 | 0 | 0 | 0 |
| Anxiety/Depression — No problems | 158 | 156 | 168 | 151 |
| Anxiety/Depression — Slight problems | 46 | 38 | 24 | 38 |
| Anxiety/Depression — Moderate problems | 3 | 9 | 8 | 8 |
| Anxiety/Depression — Severe problems | 1 | 2 | 0 | 0 |
| Anxiety/Depression — Extreme problems | 0 | 1 | 1 | 1 |
The ASC-12 includes 12 questions about the frequency of various allodynia symptoms in association with headache attacks. For individuals with more than one type of headache, questions are directed to the "most severe type of headache." Each item is measured in a Likert type scale option with response categories: "Does not apply to me", "never", "rarely", "less than half the time", and "half the time or more". ASC items were scored as 0 (i.e., never, rarely or does not apply to me), 1 (less than half the time), and 2 (half the time or more), yielding scores that ranged from 0 to 24. If a single item is missing, it is scored as a 0. If more than one item is missing the total score will be missing. The interpretation of the total score is, 0-2: none; 3-5: mild; 6-8: moderate; greater than or equal to 9: severe.
| score on a scale | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| Change in Baseline of Allodynia Symptom Checklist-12 (ASC-12) Total Score | -1.6 ± 4.22 | -1.8 ± 3.90 | -1.6 ± 3.95 | -1.7 ± 4.33 |
Collected over Baseline to Week 56 (end of study). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 300 mg ALD403 | 0/224 (0%) | 3/224 (1.3%) | 44/224 (19.6%) |
| 100 mg ALD403 | 0/223 (0%) | 4/223 (1.8%) | 44/223 (19.7%) |
| 30 mg ALD403 | 0/219 (0%) | 4/219 (1.8%) | 44/219 (20.1%) |
| Placebo | 0/222 (0%) | 6/222 (2.7%) | 41/222 (18.5%) |
| Event | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| Hepatic CholestaticHepatobiliary disorders | 0/224 | 0/223 | 1/219 | 0/222 |
| Stomal HerniaInjury, poisoning and procedural complications | 0/224 | 0/223 | 1/219 | 0/222 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 0/224 | 0/223 | 1/219 | 0/222 |
| Acute Kidney InjuryRenal and urinary disorders | 0/224 | 0/223 | 1/219 | 0/222 |
| NephrolithiasisRenal and urinary disorders | 0/224 | 0/223 | 1/219 | 0/222 |
| CellulitisInfections and infestations | 0/224 | 0/223 | 0/219 | 1/222 |
| Intervertebral Disc ProtrusionMusculoskeletal and connective tissue disorders | 0/224 | 0/223 | 0/219 | 1/222 |
| Breast Cancer Stage IINeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/224 | 0/223 | 0/219 | 1/222 |
| MigraineNervous system disorders | 0/224 | 0/223 | 0/219 | 1/222 |
| SyncopeNervous system disorders | 0/224 | 0/223 | 0/219 | 1/222 |
| Event | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 23/224 | 22/223 | 25/219 | 16/222 |
| NasopharyngitisInfections and infestations | 14/224 | 17/223 | 14/219 | 12/222 |
| SinusitisInfections and infestations | 11/224 | 6/223 | 7/219 | 14/222 |
Safety population includes all participants who received study drug or placebo. 2 participants received duplicate randomization, participants are summarized within treatment group for which they actually received treatment.
| Age, Continuous(years) | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 40.2 ± 11.72 | 40.0 ± 10.66 | 39.1 ± 11.54 | 39.9 ± 11.67 | 39.8 ± 11.39 |
| Sex: Female, Male(Participants) | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo | Total |
|---|---|---|---|---|---|
| Female | 199 | 179 | 185 | 186 | 749 |
| Male | 25 | 44 | 34 | 36 | 139 |
| Ethnicity (NIH/OMB)(Participants) | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 40 | 42 | 45 | 34 | 161 |
| Not Hispanic or Latino | 184 | 181 | 174 | 188 | 727 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 0 | 1 | 3 |
| Asian | 1 | 1 | 1 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 0 | 1 | 3 |
| Black or African American | 27 | 17 | 31 | 30 | 105 |
| White | 187 | 196 | 180 | 181 | 744 |
| More than one race | 5 | 7 | 5 | 5 | 22 |
| Unknown or Not Reported | 1 | 1 | 2 | 2 | 6 |
| Region of Enrollment(Participants) | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo | Total |
|---|---|---|---|---|---|
| United States | 185 | 184 | 194 | 185 | 748 |
| Georgia | 39 | 39 | 25 | 37 | 140 |
| Number of migraine days(Days) | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 7.8 ± 2.59 | 7.5 ± 2.60 | 7.9 ± 2.70 | 7.5 ± 2.42 | 7.7 ± 2.58 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Sep 2015, a primary completion of Feb 2017 and a completion of Dec 2017. It does not say whether these dates are actual or estimated.
Results were first posted in May 2020, 3 years 3 months after primary completion. A results delay was requested in Sep 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eptinezumab
Alder Biopharmaceuticals, Inc. →